SHB

Summary

SHB (SH2 domain containing adaptor protein B, HGNC:10838) is a protein-coding gene on chromosome 9p13.1, encoding SH2 domain-containing adapter protein B (Q15464). Adapter protein which regulates several signal transduction cascades by linking activated receptors to downstream signaling components.

Enables phosphotyrosine residue binding activity. Predicted to be involved in signal transduction. Predicted to act upstream of or within several processes, including hematopoietic stem cell proliferation; negative regulation of oocyte maturation; and positive regulation of immune response. Located in cytoplasmic ribonucleoprotein granule; cytosol; and nucleoplasm.

Source: NCBI Gene 6461 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 126 total
• MANE Select transcript: NM_003028

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10838
Approved symbol	SHB
Name	SH2 domain containing adaptor protein B
Location	9p13.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000107338
Ensembl biotype	protein_coding
OMIM	600314
Entrez	6461

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000377707, ENST00000854896, ENST00000920838

RefSeq mRNA: 1 — MANE Select: NM_003028 NM_003028

CCDS: CCDS43806

Canonical transcript exons

ENST00000377707 — 6 exons

Exon	Start	End
ENSE00001474906	37915898	37920004
ENSE00001840732	38067929	38069227
ENSE00003617214	37955883	37956054
ENSE00003622398	37974622	37974837
ENSE00003648539	37948635	37948754
ENSE00003651206	38016011	38016131

Expression profiles

Bgee: expression breadth ubiquitous, 259 present calls, max score 93.23.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 22.4928 / max 399.7117, expressed in 1752 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
100761	21.1629	1745
100760	1.3299	809

Top tissues by expression

290 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
parotid gland	UBERON:0001831	93.23	gold quality
esophagus squamous epithelium	UBERON:0006920	89.41	gold quality
gingival epithelium	UBERON:0001949	89.05	gold quality
gingiva	UBERON:0001828	88.38	gold quality
germinal epithelium of ovary	UBERON:0001304	87.90	gold quality
squamous epithelium	UBERON:0006914	87.46	gold quality
epithelium of esophagus	UBERON:0001976	87.44	gold quality
amniotic fluid	UBERON:0000173	86.88	gold quality
ganglionic eminence	UBERON:0004023	86.15	gold quality
lower esophagus mucosa	UBERON:0035834	86.09	gold quality
pigmented layer of retina	UBERON:0001782	85.85	gold quality
cartilage tissue	UBERON:0002418	84.93	gold quality
hair follicle	UBERON:0002073	84.68	silver quality
parietal pleura	UBERON:0002400	84.65	gold quality
palpebral conjunctiva	UBERON:0001812	84.60	gold quality
vena cava	UBERON:0004087	83.26	gold quality
renal medulla	UBERON:0000362	83.16	gold quality
pleura	UBERON:0000977	82.91	gold quality
medial globus pallidus	UBERON:0002477	82.54	gold quality
visceral pleura	UBERON:0002401	82.50	gold quality
cortical plate	UBERON:0005343	82.48	gold quality
right lobe of liver	UBERON:0001114	82.17	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	82.15	gold quality
pancreatic ductal cell	CL:0002079	81.97	silver quality
right atrium auricular region	UBERON:0006631	81.73	gold quality
cardiac atrium	UBERON:0002081	81.45	gold quality
tongue squamous epithelium	UBERON:0006919	81.24	gold quality
liver	UBERON:0002107	81.16	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	81.13	gold quality
saliva-secreting gland	UBERON:0001044	81.12	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.22
E-MTAB-7303	no	848.40

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

179 targeting SHB, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-518D-5P	100.00	67.51	979
HSA-MIR-518E-5P	100.00	67.66	954
HSA-MIR-518F-5P	100.00	67.51	979
HSA-MIR-519A-5P	100.00	67.66	954
HSA-MIR-519B-5P	100.00	67.66	954
HSA-MIR-519C-5P	100.00	67.66	954
HSA-MIR-520C-5P	100.00	67.51	979
HSA-MIR-522-5P	100.00	67.66	954
HSA-MIR-523-5P	100.00	67.66	954
HSA-MIR-526A-5P	100.00	67.51	979
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-10401-5P	99.99	65.79	948

Literature-anchored findings (GeneRIF, showing 9)

• SH2-Bbeta is a Rac-binding protein that regulates cell motility (PMID:11786545)
• Shb links SLP-76 and Vav with the CD3 complex in Jurkat T cells (SLP-76) (PMID:12084069)
• SHB links IL2 receptor for signal transduction and mediates apoptosis (PMID:12200137)
• Taken together, our results suggest that SH2-Bbeta is a new signaling molecule involved in GDNF-induced neurite outgrowth. (PMID:16569669)
• It is concluded that SHB and angiogenic factors promote the development of cells expressing PDX-1 and insulin in EBs and that such cells can be separated by FACS. (PMID:16630561)
• SHB plays a role in integrating adaptive responses to various stimuli by simultaneously modulating cellular responses in different cell-types. [review] (PMID:26489764)
• It is concluded that tumor SHB gene expression relates to acute myeloid leukemia survival (PMID:28982308)
• This article provides a resource for the available molecular tools that can be used in future research on Shb (PMID:29194461)
• The Shb scaffold binds the Nck adaptor protein, p120 RasGAP, and Chimaerins and thereby facilitates heterotypic cell segregation by the receptor EphB2. (PMID:32060095)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Shb	ENSMUSG00000044813
rattus_norvegicus	Shb	ENSRNOG00000011503

Paralogs (3): SHD (ENSG00000105251), SHF (ENSG00000138606), SHE (ENSG00000169291)

Protein

Protein identifiers

SH2 domain-containing adapter protein B — Q15464 (reviewed: Q15464)

All UniProt accessions (1): Q15464

UniProt curated annotations — full annotation on UniProt →

Function. Adapter protein which regulates several signal transduction cascades by linking activated receptors to downstream signaling components. May play a role in angiogenesis by regulating FGFR1, VEGFR2 and PDGFR signaling. May also play a role in T-cell antigen receptor/TCR signaling, interleukin-2 signaling, apoptosis and neuronal cells differentiation by mediating basic-FGF and NGF-induced signaling cascades. May also regulate IRS1 and IRS2 signaling in insulin-producing cells.

Subunit / interactions. Interacts with PTPN11. Interacts with phosphorylated ‘Tyr-720’ of the ligand-activated receptor PDGFRA via its SH2 domain. Interacts with the ligand-activated receptors PDGFRB, FGFR1, KDR/VEGFR2, IL2RB and IL2RG. Interacts with EPS8 and V-SRC. Interacts with GRB2 and GRAP. Interacts with CD3Z. Interacts with tyrosine-phosphorylated LAT upon T-cell antigen receptor activation. Interacts with PLCG1. Interacts with ZAP70, LCP2/SLP-76, VAV1 and GRAP2. Interacts with JAK1 and JAK3. Interacts with PTK2/FAK1. Interacts with CRK/CrKII. Interacts with IRS2.

Subcellular location. Cytoplasm. Cell membrane.

Tissue specificity. Widely expressed.

Post-translational modifications. Phosphorylated upon PDGFRA, PDGFRB, TCR, IL2 receptor, FGFR1 or VEGFR2 activation.

Domain organisation. The SH2 domain preferentially binds phosphopeptides with the consensus sequence Y-[TVI]-X-L and mediates interaction with PDGFRA, PDGFRB, FGRFR1, IL2RB, IL2RG, CD3Z and CRK/CrKII.

Isoforms (2)

UniProt ID	Names	Canonical?
Q15464-1	1	yes
Q15464-2	2

RefSeq proteins (1): NP_003019* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000980	SH2	Domain
IPR035045	SHB_SH2	Domain
IPR036860	SH2_dom_sf	Homologous_superfamily
IPR051846	SH2_domain_adapters	Family

Pfam: PF00017

UniProt features (24 total): compositionally biased region 7, modified residue 4, region of interest 4, sequence conflict 3, splice variant 2, chain 1, domain 1, cross-link 1, mutagenesis site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q15464-F1	60.27	0.16

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 102, 307, 317, 388, 187

Mutagenesis-validated functional residues (1):

Position	Phenotype
435	loss of interaction with cd3z. alters lat, plcg1, vav1 and lcp2 phosphorylation, map kinase signaling, rac1 and jnk acti

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-4420097	VEGFA-VEGFR2 Pathway
R-HSA-162582	Signal Transduction
R-HSA-194138	Signaling by VEGF
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases

MSigDB gene sets: 265 (showing top): GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_NEGATIVE_REGULATION_OF_REPRODUCTIVE_PROCESS, GOBP_REGULATION_OF_CELL_MATURATION, GOBP_NEGATIVE_REGULATION_OF_CELL_DEVELOPMENT, GOBP_REGULATION_OF_ALPHA_BETA_T_CELL_ACTIVATION, GOBP_POSITIVE_REGULATION_OF_HEMOPOIESIS, GOBP_B_CELL_ACTIVATION, GOBP_T_CELL_ACTIVATION_INVOLVED_IN_IMMUNE_RESPONSE, GOBP_ALPHA_BETA_T_CELL_DIFFERENTIATION, GOBP_ANTIGEN_RECEPTOR_MEDIATED_SIGNALING_PATHWAY, GOBP_POSITIVE_REGULATION_OF_MITOTIC_CELL_CYCLE, GOBP_OOGENESIS, GOBP_B_CELL_PROLIFERATION, GOBP_REGULATION_OF_T_HELPER_CELL_DIFFERENTIATION, TGACCTY_ERR1_Q2

GO Biological Process (13): angiogenesis (GO:0001525), apoptotic process (GO:0006915), signal transduction (GO:0007165), B cell proliferation (GO:0042100), positive regulation of T-helper cell differentiation (GO:0045624), positive regulation of mitotic cell cycle (GO:0045931), T cell receptor signaling pathway (GO:0050852), hematopoietic stem cell proliferation (GO:0071425), negative regulation of oocyte maturation (GO:1900194), blood vessel development (GO:0001568), hemopoiesis (GO:0030097), cell differentiation (GO:0030154), blood vessel morphogenesis (GO:0048514)

GO Molecular Function (3): phosphotyrosine residue binding (GO:0001784), signaling receptor complex adaptor activity (GO:0030159), protein binding (GO:0005515)

GO Cellular Component (6): nucleoplasm (GO:0005654), cytosol (GO:0005829), plasma membrane (GO:0005886), cytoplasmic ribonucleoprotein granule (GO:0036464), cytoplasm (GO:0005737), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Signaling by VEGF	1
Signaling by Receptor Tyrosine Kinases	1
Signal Transduction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
cytoplasm	2
blood vessel morphogenesis	1
anatomical structure formation involved in morphogenesis	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
B cell activation	1
lymphocyte proliferation	1
T-helper cell differentiation	1
positive regulation of CD4-positive, alpha-beta T cell differentiation	1
regulation of T-helper cell differentiation	1
positive regulation of immune response	1
mitotic cell cycle	1
regulation of mitotic cell cycle	1
positive regulation of cell cycle	1
antigen receptor-mediated signaling pathway	1
hemopoiesis	1
stem cell proliferation	1
oocyte maturation	1
regulation of oocyte maturation	1
negative regulation of cell maturation	1
negative regulation of reproductive process	1
vasculature development	1
anatomical structure development	1
cell development	1
cellular developmental process	1
blood vessel development	1
tube morphogenesis	1
protein phosphorylated amino acid binding	1
signaling receptor binding	1
signaling adaptor activity	1
binding	1
nuclear lumen	1
membrane	1

Protein interactions and networks

STRING

470 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SHB	DHRS2	Q13268	766
SHB	SH2D2A	Q9NP31	691
SHB	SRC	P12931	618
SHB	EGF	P01133	595
SHB	P4HB	P07237	571
SHB	PTPN11	Q06124	535
SHB	GRAP2	O75791	529
SHB	PTK2	Q05397	521
SHB	LCP2	Q13094	514
SHB	HBEGF	Q99075	507
SHB	GRB2	P29354	501
SHB	SH3BP2	P78314	491
SHB	FRS2	Q8WU20	478
SHB	SHC1	P29353	473
SHB	EPS8	Q12929	466

IntAct

38 interactions, top by confidence:

A	B	Type	Score
DCAF7	DIAPH1	psi-mi:“MI:0914”(association)	0.730
NCK2	SH3PXD2B	psi-mi:“MI:0914”(association)	0.640
SLC31A1	C2orf72	psi-mi:“MI:0914”(association)	0.530
ABL1	SHB	psi-mi:“MI:0915”(physical association)	0.520
SHB	ABL1	psi-mi:“MI:0915”(physical association)	0.520
SHB	AR	psi-mi:“MI:0407”(direct interaction)	0.440
SHB	KIT	psi-mi:“MI:0407”(direct interaction)	0.440
SHB	MET	psi-mi:“MI:0407”(direct interaction)	0.440
ALK	SHB	psi-mi:“MI:0915”(physical association)	0.370
EGLN3	FAM168B	psi-mi:“MI:0914”(association)	0.350
NTAQ1	SBNO1	psi-mi:“MI:0914”(association)	0.350
YWHAG	C1orf226	psi-mi:“MI:0914”(association)	0.350
	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
YWHAG	FOXO6	psi-mi:“MI:0914”(association)	0.350
S100A2	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
FBLIM1	DCLK1	psi-mi:“MI:0914”(association)	0.350
CALM1	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
SHB	KDR	psi-mi:“MI:0914”(association)	0.350
SHB	Pdgfra	psi-mi:“MI:0914”(association)	0.350
SHB	IL2RB	psi-mi:“MI:0914”(association)	0.350
CDH1	ESYT2	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (110): ABL1 (Affinity Capture-Western), SHB (Affinity Capture-Western), SHB (Reconstituted Complex), SHB (Affinity Capture-MS), SHB (Proximity Label-MS), SHB (Affinity Capture-MS), SHB (Affinity Capture-MS), SHB (Affinity Capture-RNA), SHB (Affinity Capture-RNA), SHB (Affinity Capture-MS), KDR (Affinity Capture-Western), SHB (Proximity Label-MS), SHB (Proximity Label-MS), SHB (Proximity Label-MS), IL2RB (Reconstituted Complex)

ESM2 similar proteins: A1L3I3, A2A699, A5PKW4, A8MVW0, E7FBS9, F1MUS9, O14511, O14512, O35569, O43900, O88881, O95886, P43322, P56974, P57073, P70447, P91620, Q02297, Q04205, Q15464, Q2THW0, Q2THW8, Q2THX0, Q5DU25, Q5I1X5, Q5IS79, Q5JU85, Q5TCX8, Q5VUB5, Q5XJ13, Q66L44, Q68EF6, Q69ZH9, Q6DR98, Q6PD21, Q6T4R5, Q86X29, Q8BTH6, Q8CGB6, Q8JZP9

Diamond homologs: A6NKC9, A6X942, O88834, P00519, P00520, P00521, P10447, P20936, P29353, P32577, P41239, P41240, P41241, P42684, P50904, P98083, Q03160, Q08012, Q08CX2, Q0IIE2, Q0VBZ0, Q14451, Q15464, Q1RMW5, Q4JIM5, Q56A36, Q5SQS7, Q6AYC8, Q6PD21, Q6VYH9, Q6YKA8, Q8BI17, Q96IW2, Q96JZ2, Q9D7V1, Q9H788, Q9NP31, Q9QXK9, Q9QZC5, G5ECJ6

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 38 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Constitutive Signaling by Aberrant PI3K in Cancer	5	22.7×	5e-04
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	5	17.3×	1e-03
Intracellular signaling by second messengers	5	16.3×	1e-03
RAF/MAP kinase cascade	7	15.3×	1e-04
PIP3 activates AKT signaling	6	14.3×	5e-04
RHO GTPase Effectors	5	12.1×	2e-03
Signaling by Receptor Tyrosine Kinases	6	11.1×	1e-03
Diseases of signal transduction by growth factor receptors and second messengers	5	10.2×	3e-03

GO biological processes:

GO term	Partners	Fold	FDR
cell surface receptor protein tyrosine kinase signaling pathway	5	25.6×	8e-04
cell migration	6	10.8×	3e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

126 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	112
Likely benign	4
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

2493 predictions. Top by Δscore:

Variant	Effect	Δscore
9:37919866:AGCC:A	donor_gain	1.0000
9:37948630:CTCA:C	donor_loss	1.0000
9:37948631:TCA:T	donor_loss	1.0000
9:37948631:TCACC:T	donor_loss	1.0000
9:37948632:CAC:C	donor_loss	1.0000
9:37948632:CACCT:C	donor_loss	1.0000
9:37948633:A:C	donor_loss	1.0000
9:37948633:A:T	donor_loss	1.0000
9:37948750:ACCAT:A	acceptor_gain	1.0000
9:37948751:CCAT:C	acceptor_gain	1.0000
9:37948751:CCATC:C	acceptor_gain	1.0000
9:37948752:CAT:C	acceptor_gain	1.0000
9:37948752:CATC:C	acceptor_gain	1.0000
9:37948753:AT:A	acceptor_gain	1.0000
9:37948754:TCTG:T	acceptor_loss	1.0000
9:37948755:C:CC	acceptor_gain	1.0000
9:37948755:C:CG	acceptor_loss	1.0000
9:37948756:T:A	acceptor_loss	1.0000
9:37955877:ACTT:A	donor_loss	1.0000
9:37955878:CTTA:C	donor_loss	1.0000
9:37955879:TTA:T	donor_loss	1.0000
9:37955879:TTACA:T	donor_loss	1.0000
9:37955880:TACAT:T	donor_loss	1.0000
9:37955881:A:AC	donor_gain	1.0000
9:37955881:ACATT:A	donor_loss	1.0000
9:37955882:C:A	donor_loss	1.0000
9:37955882:C:CA	donor_gain	1.0000
9:37955882:CA:C	donor_gain	1.0000
9:37955882:CAT:C	donor_gain	1.0000
9:37955882:CATT:C	donor_gain	1.0000

AlphaMissense

3285 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:37919852:A:G	L500P	1.000
9:37919852:A:T	L500H	1.000
9:37919882:A:G	L490P	1.000
9:37919882:A:T	L490Q	1.000
9:37919898:A:C	Y485D	1.000
9:37919918:A:T	V478D	1.000
9:37919926:G:C	F475L	1.000
9:37919926:G:T	F475L	1.000
9:37919928:A:G	F475L	1.000
9:37948638:A:G	L448P	1.000
9:37948644:A:G	L446P	1.000
9:37948644:A:T	L446H	1.000
9:37948677:C:G	R435P	1.000
9:37948680:A:T	V434D	1.000
9:37948683:A:G	L433P	1.000
9:37948683:A:T	L433H	1.000
9:37948687:A:C	Y432D	1.000
9:37948687:A:T	Y432N	1.000
9:37948688:G:C	S431R	1.000
9:37948688:G:T	S431R	1.000
9:37948690:T:G	S431R	1.000
9:37948710:A:G	L424P	1.000
9:37948713:A:G	L423P	1.000
9:37948722:G:T	A420D	1.000
9:37948747:G:C	H412D	1.000
9:37948750:A:C	Y411D	1.000
9:37948751:C:A	W410C	1.000
9:37948751:C:G	W410C	1.000
9:37948753:A:G	W410R	1.000
9:37948753:A:T	W410R	1.000

dbSNP variants (sampled 300 via entrez): RS1000002368 (9:38046259 C>T), RS1000013707 (9:37920769 G>C), RS1000018321 (9:38034420 G>A), RS1000030414 (9:37997047 T>C,G), RS1000045699 (9:38022228 A>G), RS1000054097 (9:38009836 T>C,G), RS1000067454 (9:37920358 A>C), RS1000069051 (9:37958972 A>G), RS1000084226 (9:38033892 G>A), RS1000095128 (9:37942346 C>A), RS1000103749 (9:37996748 A>G), RS1000104224 (9:37979526 T>C), RS1000120817 (9:38011151 G>A,C), RS1000129209 (9:38049514 G>A,C), RS1000129932 (9:38039454 G>A)

Disease associations

OMIM: gene MIM:600314 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST000597_12	Brain structure	6.000000e-07
GCST002120_9	Metabolite levels (Dihydroxy docosatrienoic acid)	5.000000e-06
GCST003772_14	Loneliness (linear analysis)	2.000000e-06
GCST004125_12	Type 2 diabetes (age of onset)	4.000000e-06
GCST007096_135	Pulse pressure	7.000000e-09
GCST007097_64	Pulse pressure	4.000000e-06
GCST007099_140	Systolic blood pressure	3.000000e-06
GCST007576_198	Chronotype	5.000000e-08
GCST012419_2	Longevity (100 years and older)	2.000000e-09

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0005275	dihydroxy docosatrienoic acid measurement
EFO:0007865	loneliness measurement
EFO:0005763	pulse pressure measurement
EFO:0006335	systolic blood pressure
EFO:0008328	chronotype measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PubChem BioAssay actives

6 with measured affinity, of 10 total; 6 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
[4-[2-acetamido-3-[1-(3-carbamoyl-4-hepta-1,6-dien-4-yloxyphenyl)ethylamino]-3-oxopropyl]cyclohexa-1,3-dien-1-yl] dihydrogen phosphate	1799894: Fluorescence Polarization Assay from Article 10.1021/cc990074a: “Structure-based design and solid-phase parallel synthesis of phosphorylated nonpeptides to explore hydrophobic binding at the Src SH2 domain.”	ic50	0.9000	uM
[4-[2-acetamido-3-[1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethylamino]-3-oxopropyl]phenyl] dihydrogen phosphate	1799894: Fluorescence Polarization Assay from Article 10.1021/cc990074a: “Structure-based design and solid-phase parallel synthesis of phosphorylated nonpeptides to explore hydrophobic binding at the Src SH2 domain.”	ic50	1.9000	uM
[4-[2-acetamido-3-[1-(3-carbamoyl-4-cyclohexyloxyphenyl)ethylamino]-3-oxopropyl]cyclohexa-1,3-dien-1-yl] dihydrogen phosphate	1799894: Fluorescence Polarization Assay from Article 10.1021/cc990074a: “Structure-based design and solid-phase parallel synthesis of phosphorylated nonpeptides to explore hydrophobic binding at the Src SH2 domain.”	ic50	2.6000	uM
[4-[[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]methylcarbamoyl]phenyl] dihydrogen phosphate	1799894: Fluorescence Polarization Assay from Article 10.1021/cc990074a: “Structure-based design and solid-phase parallel synthesis of phosphorylated nonpeptides to explore hydrophobic binding at the Src SH2 domain.”	ic50	6.5000	uM
[4-[2-acetamido-3-[1-[3-carbamoyl-4-(3-phenylpropoxy)phenyl]ethylamino]-3-oxopropyl]cyclohexa-1,3-dien-1-yl] dihydrogen phosphate	1799894: Fluorescence Polarization Assay from Article 10.1021/cc990074a: “Structure-based design and solid-phase parallel synthesis of phosphorylated nonpeptides to explore hydrophobic binding at the Src SH2 domain.”	ic50	6.5000	uM
[4-[2-acetamido-3-[1-(3-carbamoyl-4-propan-2-yloxyphenyl)ethylamino]-3-oxopropyl]cyclohexa-1,3-dien-1-yl] dihydrogen phosphate	1799894: Fluorescence Polarization Assay from Article 10.1021/cc990074a: “Structure-based design and solid-phase parallel synthesis of phosphorylated nonpeptides to explore hydrophobic binding at the Src SH2 domain.”	ic50	7.5000	uM

CTD chemical–gene interactions

57 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, increases methylation	4
entinostat	increases expression, affects cotreatment	2
Resveratrol	increases expression, affects cotreatment, decreases expression	2
Panobinostat	affects cotreatment, increases expression	2
Estradiol	increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Cyclosporine	increases expression	2
FR900359	affects phosphorylation	1
bisphenol F	affects cotreatment, increases methylation	1
TAK-243	increases sumoylation	1
methylmercuric chloride	increases expression	1
bisphenol A	affects methylation, affects cotreatment, increases methylation	1
ethyl-p-hydroxybenzoate	increases expression	1
trichostatin A	increases expression	1
afimoxifene	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	increases expression	1
benzo(e)pyrene	decreases methylation	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
bisphenol S	decreases methylation	1
PCI 5002	affects cotreatment, increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Leflunomide	increases expression	1
Acetaminophen	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Antimycin A	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.